Community Acquired Pneumonia (CAP) R&D Pipeline Analysis Report, Q4 2020
Community Acquired Pneumonia (CAP) Pipeline Overview
The Q4 Community Acquired Pneumonia (CAP) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Community Acquired Pneumonia (CAP), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Community Acquired Pneumonia (CAP) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Community Acquired Pneumonia (CAP) disease overview, Community Acquired Pneumonia (CAP) types, Community Acquired Pneumonia (CAP) symptoms, causes, and FDA/EMA approved treatment options.
Community Acquired Pneumonia (CAP) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Community Acquired Pneumonia (CAP) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Community Acquired Pneumonia (CAP) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 17 companies. Business profiles and contact details of the companies actively perusing Community Acquired Pneumonia (CAP) pipeline are assessed.
Community Acquired Pneumonia (CAP) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Community Acquired Pneumonia (CAP) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Community Acquired Pneumonia (CAP) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Community Acquired Pneumonia (CAP) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Community Acquired Pneumonia (CAP) Pipeline Market News and Developments during 2020
The Community Acquired Pneumonia (CAP) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Community Acquired Pneumonia (CAP) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Community Acquired Pneumonia (CAP) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Community Acquired Pneumonia (CAP), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Community Acquired Pneumonia (CAP) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Community Acquired Pneumonia (CAP) disease overview, Community Acquired Pneumonia (CAP) types, Community Acquired Pneumonia (CAP) symptoms, causes, and FDA/EMA approved treatment options.
Community Acquired Pneumonia (CAP) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Community Acquired Pneumonia (CAP) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Community Acquired Pneumonia (CAP) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 17 companies. Business profiles and contact details of the companies actively perusing Community Acquired Pneumonia (CAP) pipeline are assessed.
Community Acquired Pneumonia (CAP) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Community Acquired Pneumonia (CAP) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Community Acquired Pneumonia (CAP) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Community Acquired Pneumonia (CAP) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Community Acquired Pneumonia (CAP) Pipeline Market News and Developments during 2020
The Community Acquired Pneumonia (CAP) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Community Acquired Pneumonia (CAP) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Community Acquired Pneumonia (CAP) pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 17 companies are included including Basilea Pharmaceutica Ltd , BioAegis Therapeutics Inc, Biotest AG , Combioxin SA, InflaRx NV, ioGenetics, LLC, Iterum Therapeutics Plc , KYORIN Pharmaceutical Co.,Ltd, La Jolla Pharmaceutical Company, Meiji Seika Pharma Co Ltd, Merck & Co Inc, Nabriva Therapeutics Plc, Paratek Pharmaceuticals, Inc., ProThera Biologics LLC, TaiGen Biotechnology Co., Ltd., TiGenix NV, Wockhardt Ltd,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Community Acquired Pneumonia (CAP) pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Community Acquired Pneumonia (CAP) Pipeline, 2020
2.2 Most focused Mechanism of Action in Community Acquired Pneumonia (CAP) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Community Acquired Pneumonia (CAP) pipeline
2.5 Active Companies Developing Community Acquired Pneumonia (CAP) pipeline
3. COMMUNITY ACQUIRED PNEUMONIA (CAP) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Basilea Pharmaceutica Ltd
BioAegis Therapeutics Inc
Biotest AG
Combioxin SA
InflaRx NV
ioGenetics
LLC
Iterum Therapeutics Plc
KYORIN Pharmaceutical Co.
-Ltd
La Jolla Pharmaceutical Company
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Nabriva Therapeutics Plc
Paratek Pharmaceuticals
Inc.
ProThera Biologics LLC
TaiGen Biotechnology Co.
Ltd.
TiGenix NV
Wockhardt Ltd
5. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Community Acquired Pneumonia (CAP) Pipeline, 2020
2.2 Most focused Mechanism of Action in Community Acquired Pneumonia (CAP) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Community Acquired Pneumonia (CAP) pipeline
2.5 Active Companies Developing Community Acquired Pneumonia (CAP) pipeline
3. COMMUNITY ACQUIRED PNEUMONIA (CAP) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Basilea Pharmaceutica Ltd
BioAegis Therapeutics Inc
Biotest AG
Combioxin SA
InflaRx NV
ioGenetics
LLC
Iterum Therapeutics Plc
KYORIN Pharmaceutical Co.
-Ltd
La Jolla Pharmaceutical Company
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Nabriva Therapeutics Plc
Paratek Pharmaceuticals
Inc.
ProThera Biologics LLC
TaiGen Biotechnology Co.
Ltd.
TiGenix NV
Wockhardt Ltd
5. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. COMMUNITY ACQUIRED PNEUMONIA (CAP) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
